2022
DOI: 10.5489/cuaj.8148
|View full text |Cite
|
Sign up to set email alerts
|

UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(7 citation statements)
references
References 46 publications
0
7
0
Order By: Relevance
“…Darolutamide is recommended as a treatment option for mHSPC in North American guidelines [ 6 , 7 ]. The US National Comprehensive Cancer Network recommends darolutamide in combination with ADT and docetaxel as a preferred treatment option for the treatment of mHSPC, particularly for patients who have high-volume disease and are candidates for chemotherapy [ 6 ].…”
Section: Place Of Darolutamide In the Management Of Prostate Cancermentioning
confidence: 99%
See 2 more Smart Citations
“…Darolutamide is recommended as a treatment option for mHSPC in North American guidelines [ 6 , 7 ]. The US National Comprehensive Cancer Network recommends darolutamide in combination with ADT and docetaxel as a preferred treatment option for the treatment of mHSPC, particularly for patients who have high-volume disease and are candidates for chemotherapy [ 6 ].…”
Section: Place Of Darolutamide In the Management Of Prostate Cancermentioning
confidence: 99%
“…The US National Comprehensive Cancer Network recommends darolutamide in combination with ADT and docetaxel as a preferred treatment option for the treatment of mHSPC, particularly for patients who have high-volume disease and are candidates for chemotherapy [ 6 ]. The Canadian Urological Association recommends systemic triple therapy in patients who can safely tolerate docetaxel and if docetaxel treatment is appropriate [ 7 ]. Treatment with darolutamide plus ADT and docetaxel is recommended for mHSPC regardless of disease volume, as the effect of disease volume in ARASENS was reported after the publication of these guidelines [ 7 ].…”
Section: Place Of Darolutamide In the Management Of Prostate Cancermentioning
confidence: 99%
See 1 more Smart Citation
“…This was aligned with a published CADTH provisional funding algorithm, 31 a CADTH health technology review, 32 recently published Canadian guidelines, recent Canadian publications detailing practice of care, and current international guidelines. [33][34][35][36][37][38] According to the literature, the goals of treatment in mCRPC include delaying disease progression, ameliorating symptoms, and improving HRQoL. 5 Likewise, clinical experts consulted by CADTH noted that the goals of treatment in the mCRPC setting include prolonged life, improved quality of life, and reduced toxicity.…”
Section: Standards Of Therapymentioning
confidence: 99%
“…Several randomized clinical trials have shown a survival benefit to adding additional systemic therapies to ADT, including docetaxel, abiraterone acetate (abiraterone), and more recently apalutamide or enzalutamide, for men with mCSPC [ 2 , 3 , 4 , 5 , 6 ]. Based on this, guidelines including those from the American Society of Clinical Oncology (ASCO) [ 7 ], European Society of Medical Oncology (ESMO) [ 8 ], as well as several national and international guidelines [ 9 , 10 , 11 ] recommend the use of ADT plus an additional systemic therapy (docetaxel, abiraterone, enzalutamide, or apalutamide) regardless of disease burden or risk. Furthermore, in patients with de novo metastatic castration-sensitive prostate cancer with high-volume disease and being offered ADT plus docetaxel, these guidelines also recommend that triplet therapy (ADT plus docetaxel plus either abiraterone and prednisone or Darolutamide) should be offered based on recent studies showing improvement in overall survival compared to ADT + docetaxel [ 12 , 13 ].…”
Section: Introductionmentioning
confidence: 99%